Membrane transporters in drug development and as determinants of precision medicine

被引:22
|
作者
Galetin, Aleksandra [1 ]
Brouwer, Kim L. R. [2 ]
Tweedie, Donald [3 ]
Yoshida, Kenta [3 ]
Sjostedt, Noora [4 ]
Aleksunes, Lauren [5 ]
Chu, Xiaoyan [6 ]
Evers, Raymond [7 ]
Hafey, Michael J. [6 ]
Lai, Yurong [8 ]
Matsson, Par [9 ]
Riselli, Andrew [10 ]
Shen, Hong [11 ]
Sparreboom, Alex [12 ]
Varma, Manthena V. S. [13 ]
Yang, Jia [10 ]
Yang, Xinning [14 ]
Yee, Sook Wah [10 ]
Zamek-Gliszczynski, Maciej J. [15 ]
Zhang, Lei [16 ]
Giacomini, Kathleen M. [10 ]
机构
[1] Univ Manchester, Ctr Appl Pharmacokinet Res, Sch Hlth Sci, Manchester, England
[2] Univ North Carolina Chapel Hill, UNC Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA
[3] Clin Pharmacol, Genentech Res & Early Dev, South San Francisco, CA USA
[4] Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, Helsinki, Finland
[5] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ USA
[6] Merck & Co Inc, Dept Pharmacokinet Dynam Metab & Bioanalyt, Rahway, NJ USA
[7] Preclin Sci & Translat Safety, Johnson & Johnson, Janssen Pharmaceut, Spring House, PA USA
[8] Gilead Sci Inc, Drug Metab, Foster City, CA USA
[9] Univ Gothenburg, Sahlgrenska Acad, Dept Pharmacol, Gothenburg, Sweden
[10] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[11] Bristol Myers Squibb Res & Dev, Dept Drug Metab & Pharmacokinet, Princeton, NJ USA
[12] Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmacol, Columbus, OH USA
[13] Pfizer Inc, Pharmacokinet Dynam & Metab, Med Design, Worldwide R&D, Groton, CT USA
[14] US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol, Silver Spring, MD USA
[15] Drug Metab & PK, GlaxoSmithKline, Collegeville, PA USA
[16] US FDA, Off Res & Stand, Off Gener Drugs, Ctr Drug Evaluat & Res CDER, Silver Spring, MD USA
基金
美国国家卫生研究院;
关键词
MDCK CELL-LINE; IN-VITRO; ENDOGENOUS BIOMARKERS; METABOLIZING-ENZYMES; EFFLUX TRANSPORTERS; P-GLYCOPROTEIN; HEPATIC-UPTAKE; QUANTITATIVE PROTEOMICS; SIMVASTATIN ACID; UPTAKE CLEARANCE;
D O I
10.1038/s41573-023-00877-1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The effect of membrane transporters on drug disposition, efficacy and safety is now well recognized. Since the initial publication from the International Transporter Consortium, significant progress has been made in understanding the roles and functions of transporters, as well as in the development of tools and models to assess and predict transporter-mediated activity, toxicity and drug-drug interactions (DDIs). Notable advances include an increased understanding of the effects of intrinsic and extrinsic factors on transporter activity, the application of physiologically based pharmacokinetic modelling in predicting transporter-mediated drug disposition, the identification of endogenous biomarkers to assess transporter-mediated DDIs and the determination of the cryogenic electron microscopy structures of SLC and ABC transporters. This article provides an overview of these key developments, highlighting unanswered questions, regulatory considerations and future directions. Significant progress has been made in understanding the influence of membrane transporters in drug disposition and response. Here, the International Transporter Consortium provides an update on the current status of membrane transporters in drug development and regulatory requirements, discusses recent scientific advances in the field and highlights future directions and unanswered questions.
引用
收藏
页码:255 / 280
页数:26
相关论文
共 50 条
  • [41] PET Molecular Imaging for Precision Cancer Medicine and Efficient Drug Development
    Watanabe, Yasuyoshi
    CANCER SCIENCE, 2018, 109 : 555 - 555
  • [42] CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine
    Chanchal, Dilip Kumar
    Chaudhary, Jitendra Singh
    Kumar, Pushpendra
    Agnihotri, Neha
    Porwal, Prateek
    CURRENT GENE THERAPY, 2024, 24 (03) : 193 - 207
  • [43] Predictive biomarkers in precision medicine and drug development against lung cancer
    Bingliang Fang
    Reza J Mehran
    John V Heymach
    Stephen G Swisher
    Chinese Journal of Cancer, 2015, 34 (07) : 295 - 309
  • [44] Human biomimetic liver microphysiology systems in drug development and precision medicine
    Albert Gough
    Alejandro Soto-Gutierrez
    Lawrence Vernetti
    Mo R. Ebrahimkhani
    Andrew M. Stern
    D. Lansing Taylor
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 : 252 - 268
  • [45] Predictive biomarkers in precision medicine and drug development against lung cancer
    Fang, Bingliang
    Mehran, Reza J.
    Heymach, John V.
    Swisher, Stephen G.
    CHINESE JOURNAL OF CANCER, 2015, 34
  • [46] Renal Transporters in Drug Development
    Morrissey, Kari M.
    Stocker, Sophie L.
    Wittwer, Matthias B.
    Xu, Lu
    Giacomini, Kathleen M.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013, 2013, 53 : 503 - +
  • [47] Role of Transporters in Drug Development
    Arya, Vikram
    Kiser, Jennifer J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 : S7 - S10
  • [48] Transporters and new drug development
    Endou, H
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 6P - 6P
  • [49] Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
    Liu, Johnson J.
    Lu, Jun
    McKeage, Mark J.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (08) : 962 - 986
  • [50] Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
    Koenig, Joerg
    Mueller, Fabian
    Fromm, Martin F.
    PHARMACOLOGICAL REVIEWS, 2013, 65 (03) : 944 - 966